NACA Tablets Inhibit Vision Reduction in Usher Syndrome Patients
Summary
The USPTO has published a patent application (US20260083688A1) detailing compositions and methods for treating Usher syndrome associated retinitis pigmentosa using N-acetylcysteine amide (NACA) tablets. The application outlines specific dosages and claims to inhibit vision degradation and protect retinal sensitivity in patients.
What changed
This document is a USPTO patent application (US20260083688A1) for a pharmaceutical treatment involving N-acetylcysteine amide (NACA) tablets designed to inhibit vision reduction in patients with Usher syndrome associated retinitis pigmentosa (UARP). The application specifies methods for identifying patients with UARP and administering effective amounts of NACA to protect vision, inhibit degradation of the Ellipsoid Zone (EZ) area, and preserve retinal sensitivity, with example dosages ranging from 50 to 1,000 mg/day.
As this is a patent application, it does not impose immediate regulatory obligations on pharmaceutical companies or healthcare providers. However, it signals potential future developments in treatments for UARP. Companies involved in ophthalmology, pharmaceutical development, or related research may wish to monitor the progress of this patent application and similar innovations in the field. The filing date was September 24, 2025.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis Pigmentosa
Application US20260083688A1 Kind: A1 Mar 26, 2026
Inventors
G. Michael Wall, Jami Kern
Abstract
Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg/day.
CPC Classifications
A61K 31/16 A61P 27/02
Filing Date
2025-09-24
Application No.
19338733
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.